Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,772 signal articles · 78 in last 24h · 148,324 total before filter · latest 45m ago
78last 24h
978last 7d
110● bullish (7d)
126● bearish (7d)
212publishers
AllMacro369Earnings115M&A99Regulatory8Product11Analyst12
✕ clear all filtersticker: LCIDSentiment:bullishneutralbearishshow all (incl. clickbait)
Is Tesla Stock Priced For Its Earnings Or Its Robots?
Trefis7d agoneutral
Is Tesla Stock Priced For Its Earnings Or Its Robots?

Tesla (TSLA) stock trades at about $364, roughly 169 times its adjusted earnings over the past twelve months, meaning normalized net income with stock-based compensation added back. On analysts' own 2027 estimates, the multiple is still steep. So the price leans on wider margins and on products still early in their ramps.

Lucid Group Q2 Earnings Call Highlights
MarketBeat45d agoneutral
Lucid Group Q2 Earnings Call Highlights

Lucid Group (NASDAQ:LCID) outlined a broad operational reset during its second-quarter 2026 earnings call, with newly appointed CEO Silvio Napoli saying the electric-vehicle maker is targeting approximately $1.4 billion in cash-flow improvements this year while reducing production, lowering inventor

Citi Cuts Lucid Price Target to $14: Q1 Miss, Pulled Guidance Test the Saudi-Backed EV Maker
24/7 Wall St.127d agobearish
Citi Cuts Lucid Price Target to $14: Q1 Miss, Pulled Guidance Test the Saudi-Backed EV Maker

Citi just trimmed its price target on Lucid Group (NASDAQ:LCID) to $14 from $17, while keeping a Buy rating. Analyst Michael Ward cited the company’s Q1 2026 miss and the withdrawal of its 2026 outlook, but argued the medium-term thesis remains intact. For long-term investors, the price target cut reads as a sobering near-term recalibration ... Citi Cuts Lucid Price Target to $14: Q1 Miss, Pulled Guidance Test the Saudi-Backed EV Maker

Lucid Diagnostics Q1 Earnings Call Highlights
MarketBeat127d agoneutral
Lucid Diagnostics Q1 Earnings Call Highlights

Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health sys